Valuation: argenx SE

Market Cap 56.16B 50.19B 46.21B 41.96B 78.54B 5,347B 80.01B 552B 220B 2,802B 211B 206B 8,858B P/E 2026 *
30x
P/E 2027 * 26.2x
Enterprise Value 52.34B 46.77B 43.07B 39.1B 73.19B 4,983B 74.57B 515B 205B 2,612B 196B 192B 8,256B EV / Sales 2026 *
8.21x
EV / Sales 2027 * 6.46x
Free-Float
99.99%
Yield 2026 *
0.04%
Yield 2027 * 0.09%
1 day+0.98%
1 week+2.26%
Current month-5.01%
1 month-4.76%
3 months+4.20%
6 months+20.85%
Current year+12.22%
1 week 771.2
Extreme 771.2
815.6
1 month 682
Extreme 682
862.4
Current year 568.4
Extreme 568.4
925
1 year 568.4
Extreme 568.4
925
3 years 271
Extreme 271
925
5 years 224.1
Extreme 224.1
925
10 years 12.5
Extreme 12.5
925
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2026
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Chairman 54 06/05/2026
Director/Board Member 76 13/05/2015
Director/Board Member 65 28/04/2016
Date Insider Type Main position Quantity % Market Cap. Importance
23/11/25 Sell

Director

4,680 0.0076%
23/11/25 Exercice

Director

4,680 0.0076%
23/11/25 Exercice

Chief Executive Officer

2,000 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
+0.98%+2.26%+12.91%+82.98% 55.53B
+0.34%-3.03%+37.45%+61.06% 64.14B
+1.75%+2.76%+12.38%+103.69% 53.03B
-1.43%-0.57%+26.10%+52.86% 45.99B
-0.48%-3.86%+17.27%+117.99% 42.45B
+0.82%-2.06%+227.09%+922.41% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+44.58%+102.84%+88.74% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
+1.30%-2.37%-15.14%-2.27% 22.1B
Average -0.18%+3.08%+45.43%+146.70% 41.46B
Weighted average by Cap. -0.00%+2.77%+45.83%+152.19%

Financials

2026 *2027 *
Net sales 6.37B 5.69B 5.24B 4.76B 8.91B 607B 9.08B 62.67B 24.98B 318B 23.91B 23.4B 1,005B 7.77B 6.95B 6.4B 5.81B 10.87B 740B 11.08B 76.46B 30.47B 388B 29.18B 28.56B 1,226B
Net income 1.83B 1.63B 1.5B 1.36B 2.55B 174B 2.6B 17.96B 7.16B 91.1B 6.85B 6.71B 288B 2.11B 1.89B 1.74B 1.58B 2.95B 201B 3.01B 20.78B 8.28B 105B 7.93B 7.76B 333B
Net Debt -3.82B -3.42B -3.14B -2.86B -5.34B -364B -5.45B -37.59B -14.98B -191B -14.34B -14.04B -603B -5.91B -5.28B -4.86B -4.41B -8.26B -562B -8.42B -58.1B -23.16B -295B -22.17B -21.7B -932B
Projected Income Statement - Annual - argenx SE
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
29/10/26 €804.40 +0.98% 62,464
28/10/26 €796.60 +1.76% 67,787
27/10/26 €782.80 +0.33% 60,326
26/10/26 €780.20 -0.26% 65,204
23/10/26 €782.20 -0.15% 105,922
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - argenx SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
898.07USD
Average target price
1,121.73USD
Spread / Average Target
+24.90%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - argenx SE
  1. Stock Market
  2. Stocks
  3. ARGX Stock